Amphastar Pharmaceuticals (AMPH) Short term Debt (2013 - 2026)

Amphastar Pharmaceuticals has reported Short term Debt for 14 years, with the latest figure at $2.5 million in Q2 2026.

• On a quarterly basis, Short term Debt rose 168.39% year-over-year to $2.5 million in Q2 2026; TTM through Jun 2026 was $2.5 million, a 168.39% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 601.28% from the prior year.
• Short term Debt was $2.5 million for Q2 2026 at Amphastar Pharmaceuticals, up from $1.7 million in the prior quarter.
• The five-year high for Short term Debt was $12.9 million in Q2 2023, with the low at $224000.0 in Q1 2025.
• Average Short term Debt over 5 years is $1.9 million, with a median of $1.3 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2026: Short term Debt slumped 98.07% in 2024, then jumped 645.98% in 2026.
• Over 5 years, Short term Debt stood at $3.0 million in 2022, then plunged by 85.69% to $436000.0 in 2023, then tumbled by 46.33% to $234000.0 in 2024, then jumped by 601.28% to $1.6 million in 2025, then soared by 51.61% to $2.5 million in 2026.
• The last three Short term Debt figures came in at $2.5 million (Q2 2026), $1.7 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.